Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology

Building Your Care Team and Staying Proactive

At a Glance

Managing Polycythemia Vera (PV) requires an active partnership with an MPN specialist and regular blood count monitoring. Combining specialized medical care with heart-healthy lifestyle habits, like staying hydrated and eating an anti-inflammatory diet, is crucial for long-term health.

Managing Polycythemia Vera (PV) is a long-term commitment that requires a partnership between you and your medical team. Because PV is a rare disease, the quality of your specialized care and your own lifestyle choices play a significant role in your long-term health [1][2].

Why a Specialist Matters

While a general hematologist treats many blood disorders, an MPN Specialist focuses specifically on Myeloproliferative Neoplasms like PV [1].

  • Precision Diagnosis: Specialized centers use advanced molecular testing, such as Next-Generation Sequencing (NGS), to identify specific genetic markers that can help predict how your disease might behave [3][4].
  • Cutting-Edge Care: Specialists are more likely to be familiar with the latest therapeutic goals, such as using interferons for “disease modification” rather than just symptom control [5][6].
  • Clinical Trial Access: Specialized centers often host trials for new medications that are not yet available at local clinics [7][8].

Your Surveillance Schedule

Monitoring your disease requires regular Complete Blood Count (CBC) tests. The frequency of these tests typically follows two phases [9][10]:

  1. The Induction Phase (Getting Control):
    When you are first diagnosed or starting a new medication, your doctor needs to see how your body reacts. You may need blood work as often as once or twice a week until your hematocrit is consistently below 45% [9][10].
  2. The Maintenance Phase (Staying Controlled):
    Once your counts are stable and your medication dose is set, the frequency usually decreases. You may transition to blood work every 4 to 12 weeks, depending on your specific risk level and treatment [11][12].

Lifestyle as Medicine

In addition to medication, you can take active steps to reduce the “sluggishness” of your blood and protect your heart [2].

  • Diet: Emerging MPN research suggests an anti-inflammatory diet, such as the Mediterranean diet, may help reduce your overall symptom burden and lower cardiovascular risk [13].
  • Hydration: Drinking plenty of water is essential. Dehydration can lead to hemoconcentration, which makes your blood even thicker and harder to pump, potentially increasing your risk of symptoms like headaches or dizziness [14][15].
  • Cardiovascular Health: Since blood clots are the primary risk in PV, managing other “heart-health” factors is critical. This includes [2][16]:
    • Smoking Cessation: Smoking significantly increases the risk of arterial blood clots and can even trigger the body to make more red blood cells [17].
    • Blood Pressure & Cholesterol: Work with your primary care doctor to ensure your blood pressure and lipids are within a healthy range [18][13].
  • Activity: Regular, moderate exercise helps improve circulation and can help manage common symptoms like fatigue [19][13].

Creating a “Safety Net”

You are the most important member of your care team. Keeping a log of your lab results—especially your Hematocrit (HCT), White Blood Cell (WBC) count, and Platelets—allows you to see trends over time [9]. If you ever feel that your symptoms are being overlooked or your treatment isn’t meeting the “under 45%” goal, don’t hesitate to seek a second opinion from a dedicated MPN center [1][2].

Common questions in this guide

Why should I see an MPN specialist for Polycythemia Vera?
An MPN specialist focuses specifically on blood cancers like Polycythemia Vera. They offer access to advanced genetic testing, the latest treatment goals like disease modification, and clinical trials that a general hematologist might not provide.
How often do I need blood tests for Polycythemia Vera?
When first diagnosed or starting a new medication, you may need blood tests once or twice a week to monitor your counts. Once your condition is stable, testing usually decreases to every 4 to 12 weeks depending on your treatment plan.
What lifestyle changes help manage Polycythemia Vera?
Staying well-hydrated, eating an anti-inflammatory diet, getting regular exercise, and quitting smoking can significantly help. These habits help prevent blood from becoming too thick and protect your cardiovascular health.
Why is hydration so important if I have Polycythemia Vera?
Dehydration can lead to hemoconcentration, which makes your blood even thicker and harder for your heart to pump. Drinking plenty of water helps reduce symptoms like headaches and dizziness by keeping your blood flowing smoothly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with Polycythemia Vera (PV) do you currently manage in your practice?
  2. 2.Do you follow the NCCN or ELN guidelines for risk stratification and treatment targets?
  3. 3.Can you provide me with a written schedule for how often my blood counts will be checked?
  4. 4.If my condition starts to change, do you have a relationship with an MPN specialist at a major academic center for a second opinion?
  5. 5.Are there any clinical trials for PV that I might be a candidate for, now or in the future?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Next Generation Sequencing Identifies Subgroups of Patients With Triple Negative Primary Thrombocytosis With Different Clinical Thrombotic Outcomes.

    Sangiorgio V, Mottadelli F, Pagni F, et al.

    International journal of laboratory hematology 2025; (47(5)):869-876 doi:10.1111/ijlh.14476.

    PMID: 40190073
  2. 2

    Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.

    Benevolo G, Marchetti M, Melchio R, et al.

    Vascular health and risk management 2023; (19()):765-778 doi:10.2147/VHRM.S429995.

    PMID: 38025519
  3. 3

    Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs).

    Ma X, Zhou Z, Gu S, et al.

    Cancers 2025; (17(19)) doi:10.3390/cancers17193142.

    PMID: 41097669
  4. 4

    Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

    Tefferi A, Barbui T

    Mayo Clinic proceedings 2015; (90(9)):1283-93.

    PMID: 26355403
  5. 5

    Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians.

    Kuykendall AT, Fine JT, Kremyanskaya M

    Clinical lymphoma, myeloma & leukemia 2024; (24(8)):512-522 doi:10.1016/j.clml.2024.04.003.

    PMID: 38749802
  6. 6

    A safety evaluation of ruxolitinib for the treatment of polycythemia vera.

    Boldrini V, Vannucchi AM, Guglielmelli P

    Expert opinion on drug safety 2024; (23(1)):1-7 doi:10.1080/14740338.2023.2299391.

    PMID: 38156903
  7. 7

    Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

    Yacoub A, Mascarenhas J, Kosiorek H, et al.

    Blood 2019; (134(18)):1498-1509 doi:10.1182/blood.2019000428.

    PMID: 31515250
  8. 8

    SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.

    Masarova L, Chifotides HT

    Clinical lymphoma, myeloma & leukemia 2024; (24(3)):141-148 doi:10.1016/j.clml.2023.11.004.

    PMID: 38135633
  9. 9

    A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

    McMullin MFF, Mead AJ, Ali S, et al.

    British journal of haematology 2019; (184(2)):161-175 doi:10.1111/bjh.15647.

    PMID: 30426472
  10. 10

    Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.

    Chew LP, Ginzburg YZ, Kirubamoorthy K, et al.

    Leukemia research 2025; (159()):108132 doi:10.1016/j.leukres.2025.108132.

    PMID: 41175501
  11. 11

    Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

    Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, et al.

    Haematologica 2017; (102(1)):103-109 doi:10.3324/haematol.2016.152769.

    PMID: 27686377
  12. 12

    How I treat polycythemia vera.

    Spivak JL

    Blood 2019; (134(4)):341-352 doi:10.1182/blood.2018834044.

    PMID: 31151982
  13. 13

    Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.

    Skov V, Thomassen M, Kjaer L, et al.

    European journal of haematology 2023; (111(5)):805-814 doi:10.1111/ejh.14081.

    PMID: 37640394
  14. 14

    Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis.

    Gordeuk VR, Key NS, Prchal JT

    Haematologica 2019; (104(4)):653-658 doi:10.3324/haematol.2018.210732.

    PMID: 30872370
  15. 15

    Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

    Gerds AT, Mesa R, Burke JM, et al.

    Blood 2024; (143(16)):1646-1655 doi:10.1182/blood.2023020232.

    PMID: 38142448
  16. 16

    Contemporary approach to essential thrombocythemia and polycythemia vera.

    Aruch D, Mascarenhas J

    Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

    PMID: 26717193
  17. 17

    Erythrocytosis and CKD: A Review.

    Aoun M, Jadoul M, Anders HJ

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(4)):495-506 doi:10.1053/j.ajkd.2024.02.015.

    PMID: 38621632
  18. 18

    Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity.

    Frederiksen H, Szépligeti S, Bak M, et al.

    Clinical epidemiology 2019; (11()):955-967 doi:10.2147/CLEP.S216787.

    PMID: 31807079
  19. 19

    Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.

    Stefanou MI, Richter H, Härtig F, et al.

    European journal of neurology 2019; (26(6)):903-e64 doi:10.1111/ene.13907.

    PMID: 30629793

This page provides lifestyle and care team guidance for Polycythemia Vera for educational purposes only. Always consult your MPN specialist or hematologist for specific medical advice, treatment plans, and blood count monitoring schedules.

Get notified when new evidence is published on Polycythemia vera.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.